Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

AlzeCure Pharma

2,43 SEK

+1,25 %

Mindre end 1K følgere

ALZCUR

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+1,25 %
+22,42 %
-31,16 %
-25,44 %
+122,39 %
+110,49 %
-39,47 %
-71,19 %
-74,34 %

AlzeCure Pharma is a pharmaceutical company that researches and develops small molecule drug candidates for the treatment of diseases of the central nervous system, with a particular focus on Alzheimer's and chronic pain. The company is developing several parallel projects where the technology and research are based on its own drug platform. AlzeCure Pharma is headquartered in Huddinge, Sweden.

Læs mere
Markedsværdi
279,24 mio. SEK
Aktieomsætning
75,5 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
26.2
2026

Årsrapport '25

5.5
2026

Delårsrapport Q1'26

14.5
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse3.12.2025, 09.00

AlzeCure receives payment of EU grant for Phase 2 clinical trial with NeuroRestore ACD856 for Alzheimer's disease

AlzeCure Pharma
Pressemeddelelse14.11.2025, 11.35

Redeye: AlzeCure Pharma (Q3 Review) - Clinical phase IIa study in focus

AlzeCure Pharma
Selskabsmeddelelse11.11.2025, 07.00

AlzeCure publishes its interim report for January – September 2025

AlzeCure Pharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse14.10.2025, 06.00

Response letter to previous article published about Alzstatin's unique mode of action against Alzheimer's

AlzeCure Pharma
Pressemeddelelse7.10.2025, 08.00

AlzeCure Pharma to present at Redeye Neurology Day on October 15

AlzeCure Pharma
Pressemeddelelse8.9.2025, 08.00

Positive study results with TrkA-NAM ACD137 against knee osteoarthritis presented at pain conference NeuPSIG 2025

AlzeCure Pharma
Pressemeddelelse4.9.2025, 08.00

Data from AlzeCure's pain project ACD440 presented at the NeuPSIG 2025 pain conference

AlzeCure Pharma
Pressemeddelelse27.8.2025, 09.58

Redeye: AlzeCure Q2 - Prepares for clinical studies

AlzeCure Pharma
Selskabsmeddelelse26.8.2025, 06.00

AlzeCure publishes its interim report for January – June 2025

AlzeCure Pharma
Pressemeddelelse20.8.2025, 08.00

AlzeCure appoints Cecilia Wadell as new Head of Development

AlzeCure Pharma
Pressemeddelelse19.8.2025, 08.00

AlzeCure Pharma livestreams event about the pain project ACD440 and the opportunities within orphan drugs

AlzeCure Pharma
Pressemeddelelse5.8.2025, 08.00

New scientific data with TrkA-NAM ACD137 against knee osteoarthritis to be presented at pain conference

AlzeCure Pharma
Pressemeddelelse29.7.2025, 06.00

New scientific article published on positive clinical results with Painless ACD440 against neuropathic pain

AlzeCure Pharma
Selskabsmeddelelse24.7.2025, 09.00

AlzeCure's rights issue oversubscribed and the company resolves on a directed share issue under the framework of an overallotment option

AlzeCure Pharma
Selskabsmeddelelse24.7.2025, 08.00

AlzeCure's rights issue oversubscribed according to preliminary results

AlzeCure Pharma
Selskabsmeddelelse23.7.2025, 19.50

AlzeCure's rights issue oversubscribed according to preliminary results

AlzeCure Pharma
Pressemeddelelse21.7.2025, 08.00

AlzeCure presents ACD440 at the NeuPSIG 2025 pain conference

AlzeCure Pharma
Selskabsmeddelelse16.7.2025, 09.20

AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue

AlzeCure Pharma
Selskabsmeddelelse15.7.2025, 13.37

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma
Selskabsmeddelelse7.7.2025, 12.50

AlzeCure Pharma publishes amended Information document regarding rights issue

AlzeCure Pharma
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.